Last reviewed · How we verify
Brimonidine ophthalmic solution 0.1%
Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Brimonidine ophthalmic solution 0.1% |
|---|---|
| Sponsor | Allergan |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor (the fluid inside the eye) and enhances its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The drug has minimal systemic absorption when applied topically to the eye.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia (eye redness)
- Ocular allergic reactions
- Dry mouth
- Fatigue
- Headache
- Blurred vision
- Follicular conjunctivitis
Key clinical trials
- Upneeq vs. Lumify Ptosis (PHASE4)
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS) (NA)
- Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2% (PHASE2)
- Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy (PHASE4)
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension (PHASE4)
- Effect of Brimonidine on Corneal Thickness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine ophthalmic solution 0.1% CI brief — competitive landscape report
- Brimonidine ophthalmic solution 0.1% updates RSS · CI watch RSS
- Allergan portfolio CI